Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Feasibility of On-Site Manufacture of CD19 CAR T Cells Using the CliniMACS Prodigy in Pediatric and Young Adult Patients With Relapsed/Refractory CD19 Positive Acute Lymphoblastic Leukemia and Non-Hodgkin's Lymphoma

NCT05779930 is registered in ClinicalTrials.gov with Nationwide Children's Hospital as lead sponsor.

NCT NCT05779930
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05779930 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Feasibility of On-Site Manufacture of CD19 CAR T Cells Using the CliniMACS Prodigy in Pediatric and Young Adult Patients With Relapsed/Refractory CD19 Positive Acute Lymphoblastic Leukemia and Non-Hodgkin's Lymphoma
Lead sponsor
Nationwide Children's Hospital
Phase
Phase 1
Overall status
Not yet recruiting
Start date
October 31, 2025
Completion date
December 31, 2035
Enrollment
12 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute lymphoblastic leukemia with failed remission, acute lymphoblastic leukemia, in relapse, b cell leukemia, b-cell non hodgkin lymphoma, non-hodgkin's lymphoma refractory, non-hodgkin's lymphoma, relapsed